CHMP Adopts Positive Opinion for BMS’s Breyanzi in ≥3L R/R DLBCL
On Friday, January 28, the CHMP meeting highlights were released following Monday’s CHMP agenda. Of note, the CHMP adopted (press release) a positive opinion for Breyanzi’s (liso-cel; BMS’s CD19 CAR-T) marketing authorization in ≥3L r/r DLBCL, PMBCL, and FL grade 3B. Below, Celltelligence provides thoughts on Breyanzi’s positive CHMP opinion, while comparing Breyanzi’s regulatory EU timeline with other commercialized CAR-Ts.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.